Myriad Genetics Inc (NASDAQ:MYGN)
| Market Cap | $523.74M-29.4% |
| Revenue (ttm) | $803.60M-2.6% |
| Net Income | -$129.10M+67.8% |
| EPS | -$1.36+68.5% |
| Shares Out | 95.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jul 1, 2009 |
| Volume | 1,248,545 |
| Open | $5.45 |
| Previous Close | $5.54 |
| Day's Range | $5.31 - $5.57 |
| 52-Week Range | $2.74 - $8.09 |
| Beta | 1.61 |
| Analysts | Hold |
| Price Target | $5.42(-0.73%) |
| Earnings Date | Feb 22, 2027 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating MYGN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 22, 2027Earnings report
$MYGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MYGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MYGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MYGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MYGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MYGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MYGN
| XBIState Street SPDR S&P Biotech ETF | $16.09M |
| VTIVanguard Morningstar Total Stock Market ETF | $14.42M |
| IWMiShares Russell 2000 ETF | $13.54M |
| VXFVanguard Extended Market ETF | $6.62M |
| IWNiShares Russell 2000 Value ETF | $4.89M |
| FESMFidelity Enhanced Small Cap ETF | $4.06M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MYGN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 1.01% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.57% |
| GNOM | Global X - Genomics & Biotechnology ETF | 0.38% |
| SQLV | Royce Quant Small-Cap Quality Value ETF | 0.31% |
| DMRS | DeltaShares S&P 600 Managed Risk ETF | 0.28% |
| HAPS | Harbor Human Capital Factor US Small Cap ETF | 0.27% |
| SLY | SPDR S&P 600 Small Cap ETF | 0.18% |
| XBI | State Street SPDR S&P Biotech ETF | 0.16% |
| PQSV | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF | 0.13% |
| CAUV.TO | Avantis CIBC U.S. Small Cap Value ETF | 0.11% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.09% |
| VFVA | Vanguard U.S. Value Factor ETF | 0.08% |
Weight is the stock’s share of each fund’s holdings.
